Foreign Drug Makers Consider Japanese Market More Important Than Japanese Drug Companies
This article was originally published in PharmAsia News
Executive Summary
According to a recent survey conducted by Booz & Company on the pharmaceutical industry for the next 10 years in Japan, 38 percent of foreign pharmaceutical companies operating in Japan consider the Japanese market very important to them. In contrast, 27 percent of Japanese major pharmaceutical companies and 18 percent of middle sized drug makers share the same view. Among the major Japanese drug makers, 36 percent plans to focus on overseas market. Out of 248 target foreign and Japanese domestic companies, 35 companies answered the survey. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.